Aptevo Therapeutics effects 1-for-20 reverse stock split effective May 23, 2025

Aptevo Therapeutics Inc.

Stockholders approved reverse split 1:6 to 1:20 at May 14 special meeting; board chose 1:20 on May 21.
Filed Certificate of Amendment effective 5:01 PM ET May 23; shares trade split-adjusted from May 27.
No fractional shares issued; cash payment in lieu for stockholders; warrants rounded up to whole share.
New CUSIP 03835L 504; par value remains $0.001 per share; adjustments to options, RSUs, warrants.
Reverse split reduces outstanding shares proportionately, no change in percentage ownership for stockholders.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.99

Aptevo Therapeutics Inc.: Amended certificate of incorporation to effect a 1-for-20 reverse stock split of common stock, filed and effective May 23, 2025 (effective 2025-05-23).

Change: charter amendment
Effective: 2025-05-23

Exact text from the filing

On May 21, 2025, the Board approved an amendment to the Certificate of Incorporation to effect a reverse stock split of its common stock at the reverse split ratio of 1-for-20 (the “Reverse Stock Split”). Accordingly, on May 23, 2025, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Amendment was effective at 5:01 p.m. Eastern Time on May 23, 2025 (the “Effective Time”).

View on SEC.gov

Browse all governance changes →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-077089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.